Express Scripts Nixes Cosentyx, Neulasta in 2021 Formularies

Cigna Corp.-owned PBM Express Scripts says it will exclude nearly 150 brand medications in its 2021 National Preferred Formulary. But one consultant says only a handful of the exclusions — notably, Novartis Pharmaceuticals Corp.’s biologic Cosentyx (secukinumab) and Amgen, Inc.’s bone marrow stimulant Neulasta (pegfilgrastim) — are likely to cause much member disruption.

“They [Express Scripts] essentially said 98.7% [of customers] don’t really experience any disruption with their formulary changes,” says Stephen Wolff, Pharm.D., R.Ph., pharmacy management consultant for Milliman Inc. He notes that many of the exclusions were multi-source brands, which aren’t likely to be particularly disruptive for members. “So we’re really thinking about those 45 or so single source brands that they excluded,” Wolff tells AIS Health.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

pills-and-cash
May 9

Specialty Drug Benefits Survey Spotlights Gene Therapy, Biosimilar Strategies

READ MORE
executives-and-chart
May 9

PBMs’ 1Q Earnings Calls Are All About Biosimilar, GLP-1 Programs

READ MORE
pills-and-bottles
May 9

High Price Tag, Accelerated Approval for New NASH Drug May Give Payers Pause

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today